A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer

Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study

(2012) D. Rayson et al.   Current Oncology

Comparative Effectiveness of Filgrastim, Pegfilgrastim, and Sargramostim as Prophylaxis Against Hospitalization for Neutropenic Complications in Patients With Cancer Receiving Chemotherapy

(2011) Derek Weycker et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice—a retrospective analysis

(2010) T. Vandenberg et al.   Current Oncology

Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study

(2009) Derek Weycker et al.   CLINICAL THERAPEUTICS

Docetaxel-related side effects and their management

(2009) Jackie Baker et al.   European Journal of Oncology Nursing

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study

(2008) D. ALMENAR et al.   EUROPEAN JOURNAL OF CANCER CARE